Noticias Celltex

Celltex autologous stem cell case study published in Stem Cells and Development demonstrates positive response in pediatric patients

Celltex Therapeutics Corporation announces that Stem Cells and Development has published “Autologous Adipose Stem Cell Therapy for Autonomic Nervous System Dysfunction in Two Young Patients.” Celltex Chief Scientific Officer, Dr. Jane Shen Young, MD, PhD, is part of the research team who authored the case study focused on two pediatric autoimmune dysautonomia patients who are responding positively to autologous mesenchymal stem cell therapy using stem cells processed by Celltex.

Conducted by a panel of doctors in the Texas Medical Center, the peer-reviewed, retrospective case study presents two patients who had clearly defined autoimmune diseases and severe disabilities. Additionally, both pediatric patients had failed standard dysautonomia treatments as well as unsuccessful immunotherapy treatments. Currently, the patients are responding positively to autologous mesenchymal stem cell therapy. The doctors are suggesting further research to clearly define the effects of stem cell therapy in autoimmune dysautonomia patients.

Dr. Young has extensive academic experience in cell biology, molecular biology, protein science, biochemistry and animal models. Dr. Young is responsible for evaluating Celltex’s stem cells quality, identity, properties and clinical applications. She is supervising the production of Celltx’s mesenchymal stem cells and heavily involved in designing Celltex research, clinical studies and trials, along with physicians in multiple medical centers.

“We are very encouraged by the clinical data obtained in this study, which showed the safety and effectiveness of Celltex’s proprietary stem cell technology in dysautonomia patients,” states Dr.Young. “This study is a great representation of Celltex’s commitment to leading the United States into the future of regenerative medicine through adult stem cells.”

Celltex uses its proprietary technology which isolates, multiplies and banks autologous (one’s own) adult mesenchymal stem cells (MSCs) to be used for regenerative therapy for injuries and chronic pain as well as a number of conditions, including vascular, degenerative and autoimmune diseases.

Celltex is registered with the United States Food and Drug Administration as a Human Cell and Tissue Products (HCT/P) establishment that multiplies human cells and cellular products. The company operates in a state-of-the-art laboratory compliant with Current Good Manufacturing Practice (cGMP) standards as recommended by the FDA for the manufacturing of biological products.

To read the case study, please click here.